+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Bioengineered Protein Drugs Market by Drug Class (Enzymes, Fusion Proteins, Monoclonal Antibodies), Therapeutic Indication (Endocrinology, Hematology, Immunology), Route of Administration, End User, Technology Platform - Global Forecast 2025-2030- Product Image
Bioengineered Protein Drugs Market by Drug Class (Enzymes, Fusion Proteins, Monoclonal Antibodies), Therapeutic Indication (Endocrinology, Hematology, Immunology), Route of Administration, End User, Technology Platform - Global Forecast 2025-2030- Product Image
Sale

Bioengineered Protein Drugs Market by Drug Class (Enzymes, Fusion Proteins, Monoclonal Antibodies), Therapeutic Indication (Endocrinology, Hematology, Immunology), Route of Administration, End User, Technology Platform - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 182 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6011369
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The bioengineered protein drugs market is evolving rapidly, driven by advancements in molecular engineering, regulatory innovation, and global demand for differentiated biotherapeutic solutions. Senior leaders are prioritizing agile strategies and collaborative development to succeed in this increasingly complex ecosystem.

Market Snapshot: Bioengineered Protein Drugs Market

The Bioengineered Protein Drugs Market grew from USD 415.13 billion in 2024 to USD 448.38 billion in 2025. With an expected CAGR of 7.86%, the market is projected to achieve USD 653.87 billion by 2030. This expansion reflects sustained investment across therapeutic classes, technology platforms, and regional bioprocessing hubs. Robust growth is supported by accelerating adoption of advanced manufacturing, increasing global disease burden, and the evolving regulatory landscape.

Scope & Segmentation

This report provides analysis and forecasts across core segments, technologies, and regions shaping the competitive landscape of protein therapeutics. Segmentation covers:

  • Drug Class: Enzymes (alglucosidase, asparaginase), fusion proteins (Fc and receptor fusions), monoclonal antibodies (chimeric, fully human, humanized, murine), PEGylated proteins (interferon, expanded therapies), recombinant proteins (erythropoietin alpha/beta, key growth factors), insulin (all major types), and interferons (alpha, beta, gamma).
  • Therapeutic Indication: Endocrinology (including diabetes management), hematology (anemia, bleeding disorders), immunology (rheumatoid arthritis, IBD, psoriasis), infectious diseases (bacterial, viral), and oncology (solid tumors, hematological malignancies).
  • Route of Administration: Intramuscular, intravenous, and subcutaneous delivery approaches to address diverse patient and clinical needs.
  • End User: Clinical settings, home care, and hospitals, reflecting the importance of channel-specific approaches.
  • Technology Platform: Mammalian cell expression (CHO, NS0), microbial expression (E. coli, yeast), transgenic host systems (animal-based, plant-based) supporting platform innovation and cost optimization.
  • Regions and Countries: Americas (including U.S. by state, Canada, Mexico, Brazil, Argentina), Europe/Middle East/Africa (key EU and Gulf states, South Africa, Turkey, Israel), and Asia-Pacific (China, India, Japan, Korea, Southeast Asia, Australia).
  • Major Companies: F. Hoffmann-La Roche Ltd, AbbVie Inc., Johnson & Johnson, Amgen Inc., Novartis AG, Merck & Co Inc., Pfizer Inc., Sanofi S.A., Bristol-Myers Squibb Company, Eli Lilly and Company.

Key Takeaways

  • The market benefits from continuous innovation in genetic engineering, cell line development, and next-generation manufacturing that enhance both product quality and patient convenience.
  • Integration of artificial intelligence and structural biology shortens the discovery-to-clinic timeline, driving a robust pipeline of biosimilars and novel biologics.
  • Strategic alliances and partnerships between biotechnology firms and established pharmaceutical players are key to reducing risk and accelerating early-stage development.
  • Adaptable regulatory frameworks and collaborative global policy initiatives are streamlining approvals, improving access, and reducing time to market.
  • Diversification in manufacturing technology—such as single-use bioreactors and continuous processing—boosts scalability and supports cost management initiatives.
  • Growth is reinforced by regional investments in local capacity, regulatory harmonization, and cross-border alliances, enabling durable expansion in North America, Europe, Asia, and emerging markets.

Tariff Impact: U.S. 2025 Policy Shifts

Revised United States tariffs implemented in 2025 have affected procurement and supply chains for critical production inputs, especially for specialized growth media and consumables. In response, contract manufacturers are diversifying supplier networks, increasing localized production, and optimizing inventory strategies. These shifts are also encouraging new collaborations with partners in regions benefiting from favorable trade agreements. Companies proactively managing tariff effects through supply chain diversification and nearshoring are better positioned to sustain operational continuity.

Methodology & Data Sources

This analysis draws on primary interviews with R&D, regulatory, and supply chain leaders, combined with a review of peer-reviewed articles, regulatory filings, and industry databases. Quantitative trends are rigorously validated through scenario planning and expert workshops, ensuring actionable, credible insights.

Why This Report Matters

  • Enables strategic portfolio planning and investment prioritization aligned with current and emerging therapeutic opportunities in protein drugs.
  • Offers clear benchmarks for technology adoption, regulatory navigation, and supply chain resilience to mitigate risk and sustain market leadership.
  • Supports C-suite and senior management in evaluating partnership models, market entry strategies, and long-term growth planning.

Conclusion

This report offers senior leaders practical insights and guidance for navigating the dynamic bioengineered protein drugs market. By aligning innovation, regulatory foresight, and supply chain best practices, organizations can achieve sustained growth and deliver enhanced value to patients and stakeholders.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Advancements in bispecific antibody engineering for enhanced tumor targeting
5.2. Integration of AI-driven protein design to optimize therapeutic potency and specificity
5.3. mRNA-encoded protein therapies accelerating targeted intracellular protein expression
5.4. Scale-up challenges and innovations in continuous flow cell-free protein synthesis platforms
5.5. Expansion of biosimilar protein drug portfolios intensifying global pricing competition
5.6. Nanoparticle-based targeted delivery systems improving bioavailability of protein therapeutics
5.7. Regulatory harmonization efforts enabling faster approval pathways for novel protein drugs
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Bioengineered Protein Drugs Market, by Drug Class
8.1. Introduction
8.2. Enzymes
8.2.1. Alglucosidase
8.2.2. Asparaginase
8.3. Fusion Proteins
8.3.1. Fc Fusion Proteins
8.3.2. Receptor Fusion Proteins
8.4. Monoclonal Antibodies
8.4.1. Chimeric
8.4.2. Fully Human
8.4.3. Humanized
8.4.4. Murine
8.5. PEGylated Proteins
8.5.1. PEGylated Interferon
8.5.2. PEGylated Therapies
8.6. Recombinant Proteins
8.6.1. Erythropoietin
8.6.1.1. Alpha
8.6.1.2. Beta
8.6.2. Growth Factors
8.6.2.1. G-CSF
8.6.2.2. GM-CSF
8.6.2.3. PDGF
8.6.3. Insulin
8.6.3.1. Intermediate Acting
8.6.3.2. Long Acting
8.6.3.3. Rapid Acting
8.6.4. Interferons
8.6.4.1. Alpha
8.6.4.2. Beta
8.6.4.3. Gamma
9. Bioengineered Protein Drugs Market, by Therapeutic Indication
9.1. Introduction
9.2. Endocrinology
9.2.1. Diabetes Mellitus
9.2.2. Growth Disorders
9.3. Hematology
9.3.1. Anemia
9.3.2. Bleeding Disorders
9.4. Immunology
9.4.1. Inflammatory Bowel Disease
9.4.2. Psoriasis
9.4.3. Rheumatoid Arthritis
9.5. Infectious Diseases
9.5.1. Bacterial Infections
9.5.2. Viral Infections
9.6. Oncology
9.6.1. Hematological Malignancies
9.6.2. Solid Tumors
10. Bioengineered Protein Drugs Market, by Route of Administration
10.1. Introduction
10.2. Intramuscular
10.3. Intravenous
10.4. Subcutaneous
11. Bioengineered Protein Drugs Market, by End User
11.1. Introduction
11.2. Clinic
11.3. Home Care
11.4. Hospital
12. Bioengineered Protein Drugs Market, by Technology Platform
12.1. Introduction
12.2. Mammalian Cell Expression
12.2.1. CHO Cells
12.2.2. NS0 Cells
12.3. Microbial Expression
12.3.1. E. coli
12.3.2. Yeast
12.4. Transgenic Host Expression
12.4.1. Animal Based
12.4.2. Plant Based
13. Americas Bioengineered Protein Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Bioengineered Protein Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Bioengineered Protein Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. F. Hoffmann-La Roche Ltd
16.3.2. AbbVie Inc.
16.3.3. Johnson & Johnson
16.3.4. Amgen Inc.
16.3.5. Novartis AG
16.3.6. Merck & Co., Inc.
16.3.7. Pfizer Inc.
16.3.8. Sanofi S.A.
16.3.9. Bristol-Myers Squibb Company
16.3.10. Eli Lilly and Company
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. BIOENGINEERED PROTEIN DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. BIOENGINEERED PROTEIN DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. BIOENGINEERED PROTEIN DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. BIOENGINEERED PROTEIN DRUGS MARKET: RESEARCHAI
FIGURE 26. BIOENGINEERED PROTEIN DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 27. BIOENGINEERED PROTEIN DRUGS MARKET: RESEARCHCONTACTS
FIGURE 28. BIOENGINEERED PROTEIN DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. BIOENGINEERED PROTEIN DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENZYMES, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENZYMES, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ALGLUCOSIDASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ALGLUCOSIDASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ASPARAGINASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ASPARAGINASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENZYMES, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENZYMES, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FC FUSION PROTEINS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FC FUSION PROTEINS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RECEPTOR FUSION PROTEINS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RECEPTOR FUSION PROTEINS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FUSION PROTEINS, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FUSION PROTEINS, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY CHIMERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FULLY HUMAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FULLY HUMAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HUMANIZED, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MURINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MURINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED PROTEINS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED PROTEINS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED INTERFERON, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED INTERFERON, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED PROTEINS, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED PROTEINS, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ERYTHROPOIETIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ERYTHROPOIETIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ALPHA, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ALPHA, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BETA, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BETA, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ERYTHROPOIETIN, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ERYTHROPOIETIN, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY G-CSF, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY G-CSF, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GM-CSF, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GM-CSF, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PDGF, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PDGF, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GROWTH FACTORS, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GROWTH FACTORS, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTERMEDIATE ACTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTERMEDIATE ACTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY LONG ACTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY LONG ACTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RAPID ACTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RAPID ACTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INSULIN, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INSULIN, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTERFERONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ALPHA, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ALPHA, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BETA, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BETA, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GAMMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GAMMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTERFERONS, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTERFERONS, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DIABETES MELLITUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DIABETES MELLITUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GROWTH DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GROWTH DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENDOCRINOLOGY, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ANEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ANEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BLEEDING DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BLEEDING DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HEMATOLOGY, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HEMATOLOGY, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PSORIASIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY IMMUNOLOGY, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY IMMUNOLOGY, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 127. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 128. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 129. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 130. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 131. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 132. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 133. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 134. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 135. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 136. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 137. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 138. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 139. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 140. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 141. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 142. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 143. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY CLINIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 144. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY CLINIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 145. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 146. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 147. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 148. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 149. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
TABLE 150. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2030 (USD MILLION)
TABLE 151. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MAMMALIAN CELL EXPRESSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 152. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MAMMALIAN CELL EXPRESSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 153. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY CHO CELLS, BY REGION, 2018-2024 (USD MILLION)
TABLE 154. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY CHO CELLS, BY REGION, 2025-2030 (USD MILLION)
TABLE 155. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY NS0 CELLS, BY REGION, 2018-2024 (USD MILLION)
TABLE 156. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY NS0 CELLS, BY REGION, 2025-2030 (USD MILLION)
TABLE 157. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MAMMALIAN CELL EXPRESSION, 2018-2024 (USD MILLION)
TABLE 158. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MAMMALIAN CELL EXPRESSION, 2025-2030 (USD MILLION)
TABLE 159. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MICROBIAL EXPRESSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 160. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MICROBIAL EXPRESSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 161. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY E. COLI, BY REGION, 2018-2024 (USD MILLION)
TABLE 162. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY E. COLI, BY REGION, 2025-2030 (USD MILLION)
TABLE 163. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY YEAST, BY REGION, 2018-2024 (USD MILLION)
TABLE 164. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY YEAST, BY REGION, 2025-2030 (USD MILLION)
TABLE 165. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MICROBIAL EXPRESSION, 2018-2024 (USD MILLION)
TABLE 166. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MICROBIAL EXPRESSION, 2025-2030 (USD MILLION)
TABLE 167. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TRANSGENIC HOST EXPRESSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 168. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TRANSGENIC HOST EXPRESSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 169. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ANIMAL BASED, BY REGION, 2018-2024 (USD MILLION)
TABLE 170. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ANIMAL BASED, BY REGION, 2025-2030 (USD MILLION)
TABLE 171. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PLANT BASED, BY REGION, 2018-2024 (USD MILLION)
TABLE 172. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PLANT BASED, BY REGION, 2025-2030 (USD MILLION)
TABLE 173. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TRANSGENIC HOST EXPRESSION, 2018-2024 (USD MILLION)
TABLE 174. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TRANSGENIC HOST EXPRESSION, 2025-2030 (USD MILLION)
TABLE 175. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 176. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 177. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENZYMES, 2018-2024 (USD MILLION)
TABLE 178. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENZYMES, 2025-2030 (USD MILLION)
TABLE 179. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FUSION PROTEINS, 2018-2024 (USD MILLION)
TABLE 180. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FUSION PROTEINS, 2025-2030 (USD MILLION)
TABLE 181. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 182. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 183. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED PROTEINS, 2018-2024 (USD MILLION)
TABLE 184. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED PROTEINS, 2025-2030 (USD MILLION)
TABLE 185. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2024 (USD MILLION)
TABLE 186. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, 2025-2030 (USD MILLION)
TABLE 187. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ERYTHROPOIETIN, 2018-2024 (USD MILLION)
TABLE 188. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ERYTHROPOIETIN, 2025-2030 (USD MILLION)
TABLE 189. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GROWTH FACTORS, 2018-2024 (USD MILLION)
TABLE 190. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GROWTH FACTORS, 2025-2030 (USD MILLION)
TABLE 191. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INSULIN, 2018-2024 (USD MILLION)
TABLE 192. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INSULIN, 2025-2030 (USD MILLION)
TABLE 193. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTERFERONS, 2018-2024 (USD MILLION)
TABLE 194. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTERFERONS, 2025-2030 (USD MILLION)
TABLE 195. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 196. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 197. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2024 (USD MILLION)
TABLE 198. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENDOCRINOLOGY, 2025-2030 (USD MILLION)
TABLE 199. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HEMATOLOGY, 2018-2024 (USD MILLION)
TABLE 200. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HEMATOLOGY, 2025-2030 (USD MILLION)
TABLE 201. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY IMMUNOLOGY, 2018-2024 (USD MILLION)
TABLE 202. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY IMMUNOLOGY, 2025-2030 (USD MILLION)
TABLE 203. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 204. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 205. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 206. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 207. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 208. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 209. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 210. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 211. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
TABLE 212. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2030 (USD MILLION)
TABLE 213. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MAMMALIAN CELL EXPRESSION, 2018-2024 (USD MILLION)
TABLE 214. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MAMMALIAN CELL EXPRESSION, 2025-2030 (USD MILLION)
TABLE 215. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MICROBIAL EXPRESSION, 2018-2024 (USD MILLION)
TABLE 216. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MICROBIAL EXPRESSION, 2025-2030 (USD MILLION)
TABLE 217. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TRANSGENIC HOST EXPRESSION, 2018-2024 (USD MILLION)
TABLE 218. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TRANSGENIC HOST EXPRESSION, 2025-2030 (USD MILLION)
TABLE 219. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 220. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 221. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 222. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 223. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENZYMES, 2018-2024 (USD MILLION)
TABLE 224. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENZYMES, 2025-2030 (USD MILLION)
TABLE 225. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FUSION PROTEINS, 2018-2024 (USD MILLION)
TABLE 226. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FUSION PROTEINS, 2025-2030 (USD MILLION)
TABLE 227. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 228. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 229. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED PROTEINS, 2018-2024 (USD MILLION)
TABLE 230. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED PROTEINS, 2025-2030 (USD MILLION)
TABLE 231. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2024 (USD MILLION)
TABLE 232. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, 2025-2030 (USD MILLION)
TABLE 233. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ERYTHROPOIETIN, 2018-2024 (USD MILLION)
TABLE 234. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ERYTHROPOIETIN, 2025-2030 (USD MILLION)
TABLE 235. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GROWTH FACTORS, 2018-2024 (USD MILLION)
TABLE 236. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GROWTH FACTORS, 2025-2030 (USD MILLION)
TABLE 237. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INSULIN, 2018-2024 (USD MILLION)
TABLE 238. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INSULIN, 2025-2030 (USD MILLION)
TABLE 239. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTERFERONS, 2018-2024 (USD MILLION)
TABLE 240. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTERFERONS, 2025-2030 (USD MILLION)
TABLE 241. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 242. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 243. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2024 (USD MILLION)
TABLE 244. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENDOCRINOLOGY, 2025-2030 (USD MILLION)
TABLE 245. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HEMATOLOGY, 2018-2024 (USD MILLION)
TABLE 246. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HEMATOLOGY, 2025-2030 (USD MILLION)
TABLE 247. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY IMMUNOLOGY, 2018-2024 (USD MILLION)
TABLE 248. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY IMMUNOLOGY, 2025-2030 (USD MILLION)
TABLE 249. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 250. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 251. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 252. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 253. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 254. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 255. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 256. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 257. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
TABLE 258. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2030 (USD MILLION)
TABLE 259. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MAMMALIAN CELL EXPRESSION, 2018-2024 (USD MILLION)
TABLE 260. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MAMMALIAN CELL EXPRESSION, 2025-2030 (USD MILLION)
TABLE 261. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MICROBIAL EXPRESSION, 2018-2024 (USD MILLION)
TABLE 262. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MICROBIAL EXPRESSION, 2025-2030 (USD MILLION)
TABLE 263. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TRANSGENIC HOST EXPRESSION, 2018-2024 (USD MILLION)
TABLE 264. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TRANSGENIC HOST EXPRESSION, 2025-2030 (USD MILLION)
TABLE 265. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 266. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 267. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 268. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 269. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENZYMES, 2018-2024 (USD MILLION)
TABLE 270. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENZYMES, 2025-2030 (USD MILLION)
TABLE 271. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FUSION PROTEINS, 2018-2024 (USD MILLION)
TABLE 272. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY FUSION PROTEINS, 2025-2030 (USD MILLION)
TABLE 273. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 274. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 275. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED PROTEINS, 2018-2024 (USD MILLION)
TABLE 276. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PEGYLATED PROTEINS, 2025-2030 (USD MILLION)
TABLE 277. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2024 (USD MILLION)
TABLE 278. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, 2025-2030 (USD MILLION)
TABLE 279. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ERYTHROPOIETIN, 2018-2024 (USD MILLION)
TABLE 280. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ERYTHROPOIETIN, 2025-2030 (USD MILLION)
TABLE 281. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GROWTH FACTORS, 2018-2024 (USD MILLION)
TABLE 282. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY GROWTH FACTORS, 2025-2030 (USD MILLION)
TABLE 283. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INSULIN, 2018-2024 (USD MILLION)
TABLE 284. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INSULIN, 2025-2030 (USD MILLION)
TABLE 285. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTERFERONS, 2018-2024 (USD MILLION)
TABLE 286. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INTERFERONS, 2025-2030 (USD MILLION)
TABLE 287. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 288. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 289. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2024 (USD MILLION)
TABLE 290. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ENDOCRINOLOGY, 2025-2030 (USD MILLION)
TABLE 291. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HEMATOLOGY, 2018-2024 (USD MILLION)
TABLE 292. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HEMATOLOGY, 2025-2030 (USD MILLION)
TABLE 293. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY IMMUNOLOGY, 2018-2024 (USD MILLION)
TABLE 294. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY IMMUNOLOGY, 2025-2030 (USD MILLION)
TABLE 295. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 296. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 297. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 298. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 299. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 300. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 301. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 302. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 303. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
TABLE 304. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2030 (USD MILLION)
TABLE 305. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MAMMALIAN CELL EXPRESSION, 2018-2024 (USD MILLION)
TABLE 306. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MAMMALIAN CELL EXPRESSION, 2025-2030 (USD MILLION)
TABLE 307. CANADA

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Bioengineered Protein Drugs market report include:
  • F. Hoffmann-La Roche Ltd
  • AbbVie Inc.
  • Johnson & Johnson
  • Amgen Inc.
  • Novartis AG
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company

Table Information

Report AttributeDetails
No. of Pages182
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 448.38 Billion
Forecasted Market Value ( USD ) by 2030 $ 653.87 Billion
Compound Annual Growth Rate7.8%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Bioengineered Protein Drugs: Market Share, and Growth Analysis by Product Type (Monoclonal Antibodies, Recombinant Proteins, Fusion Proteins), Application, End User, Technology - Product Image

Bioengineered Protein Drugs: Market Share, and Growth Analysis by Product Type (Monoclonal Antibodies, Recombinant Proteins, Fusion Proteins), Application, End User, Technology

  • Report
  • 150 Pages
  • Global
From
Bioengineered Protein Drugs - Global Strategic Business Report - Product Image

Bioengineered Protein Drugs - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Bioengineered Protein Drugs Market Report 2025 - Product Image

Bioengineered Protein Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Monoclonal Antibodies for Primary Hypercholesterolemia Market by Product (Alirocumab, Evolocumab), Therapy Type (Combination Therapy, Monotherapy), Administration Method, Distribution Channel, Patient Category, End User - Global Forecast 2025-2030 - Product Image

Monoclonal Antibodies for Primary Hypercholesterolemia Market by Product (Alirocumab, Evolocumab), Therapy Type (Combination Therapy, Monotherapy), Administration Method, Distribution Channel, Patient Category, End User - Global Forecast 2025-2030

  • Report
  • 196 Pages
  • Global
From
Protein Drug Screening Validation Database Market by Technology (Cell Based Assays, High Throughput Screening, Label Free Detection), Product (Reagents, Services, Software), End User, Application - Global Forecast 2025-2030 - Product Image

Protein Drug Screening Validation Database Market by Technology (Cell Based Assays, High Throughput Screening, Label Free Detection), Product (Reagents, Services, Software), End User, Application - Global Forecast 2025-2030

  • Report
  • 184 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.